Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Gustoeson Jan 07, 2016 10:45pm
193 Views
Post# 24439028

RE:Sell device division?

RE:Sell device division?
opsd1 wrote: Someone was suggesting this to become a cancer drug company only. If the human trials are successful, Theralase is expecting between $800 million and $1.2 billion in annual revenues within a few years.
But regardless of the outcome from the human cancer trials, they are still expecting $50 million per year with the pain treatment division.
This means, at these levels at least, you can invest in a potential cure for cancer with very little downside risk.


I personally believe the hardware, being that it is almost as critical as the photosensitizer itself is a competitive advantage and should never be sold. The cold lasers stand on their own merits in pain management but as for a delivery and diagnostics capability for PDT treatment and theranostics... the tlc3xxx is extremely valuable imo. I'm actually very curious how they plan to commercialize the tlc3xxx... I'm of the thought it won't be anything like the tlc2000.. the tlc3xxx falls more in to the line of royalty/licenscing imo... there are a lot of compounds that other companies could commercialize with appropriate delivery system and Theralase can take a piece of that pie while they utilize TLT hardware for disruptive treatments in other areas that TLT is not focussing. Unless you were suggesting just to sell the tlc2000 dept but I don't see the angle there either. If TLT sees success on the upcoming trials... they can fund and fuel a powerhouse medical technology company of the future. 
Bullboard Posts